Additional material for this article is available from the James Lind Library website [http://www.jameslindlibrary.org], where this paper was previously published.
References
1.
O'BrienJ.R.An in-vivo trial of an anti-adhesive drug.Thrombosis et Diathesis Haemorrhagica1963; 9: 120–25
2.
O'BrienJ.R.Aspirin and platelet aggregation.Lancet1968; 203: 779–83
3.
O'BrienJ.R.Two in-vivo studies comparing high and low aspirin dosage.Lancet1971; 206: 399–400
4.
WeissH.J., AledortL.M.Impaired platelet/connective tissue reaction in man after aspirin ingestion.Lancet1967; 202: 495–7
5.
CravenL.L.Prevention of coronary thrombosis and acetylsalicylic acid.Mississippi Valley Med J1956; 78: 213–5
6.
JickH., VesseyM.Case-control studies in the evaluation of drug-induced illness.Am J Epidemiol1978; 107: 1–7
7.
Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction.BMJ1974; 282: 440–3
8.
ElwoodP.C., CochraneA.L., BurrM.L.. A randomised controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.BMJ1974; 282: 436–40
9.
LewisH.D., DavisJ.W., ArchibaldD.G.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans’ Administration cooperative study.NEJM1983; 309: 396–403
10.
Aspirin Myocardial Infarction Study Research Group.A randomised controlled trial of aspirin in persons recovered from myocardial infarction.JAMA1980; 243: 661–9
11.
PetoR.Aspirin after myocardial infarction.Lancet1980; 215: 1172–3 [Editorial]
12.
Antiplatelet Trialists’ Collaboration.Secondary prevention of vascular disease by prolonged anti-platelet treatment.BMJ1988; 296: 320–331
